BioSpace News Archive

Drug Development

Genentech Flu Drug Scores Another Late-Stage Win

With flu season fast approaching, Genentech has some good news for people who are at high risk of complications from the illness.

July 17, 2018
·
2 min read
·
Alex Keown
Business

HotSpot Therapeutics Emerges From Stealth Mode With $45 Million to Aim at New Biological Targets

HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.”

July 17, 2018
·
2 min read
·
Alex Keown
Drug Development

China’s Ascentage Pharma Snags $150 Million to Support Pipeline Development

One month after sharing promising interim-Phase I data at the American Society of Clinical Oncology, China-based Ascentage Pharma secured $150 million in Series C financing that will be used to support the development of its pipeline.

July 17, 2018
·
2 min read
·
Alex Keown
Business

Could Amgen Eye Alexion as a M&A Target to Offset Neulasta Decline?

With the June approval of Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s Neulasta (pegfilgrastim), the company is facing a potential revenue problem as the Mylan drug is expected to cut into Amgen’s market share.

July 17, 2018
·
2 min read
·
Alex Keown
Drug Development

Roivant Launches New China-Based Startup Sinovant Sciences

Fresh off its first Pipeline Day last week, Vivek Ramaswamy’s Roivant Sciences is taking aim at breaking into the Chinese market. Roivant has launched another company called Sinovant Sciences.

July 17, 2018
·
2 min read
·
Alex Keown
Business

Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology

Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer.

July 17, 2018
·
2 min read
·
Alex Keown
Business

AbbVie Strikes Deal With Mylan to Delay Humira Biosimilar Challenge

AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.

July 17, 2018
·
2 min read
·
Alex Keown
New Epilepsy Research at Baylor College of Medicine Provides Insight on Absence Seizures

Absence epilepsy is the most common type of seizure disorder in children and is the focus of a new neurology study at Baylor College of Medicine and published in the journal Nature Communications.

July 17, 2018
·
3 min read
·
Alex Keown